ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

GE HealthCare unveils enhanced Voluson Expert Series women’s health ultrasound systems with focus on early detection and exam efficiency

  • Latest Voluson Expert 22, 20 and 18 ultrasound systems harness artificial intelligence and advanced tools and software for more efficient assessments
  • Voluson Expert Series delivers elevated performance, with focus on first trimester to reveal clearer anatomical details, aiding earlier detection and boosting diagnostic confidence

GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the updated portfolio of Voluson™ Expert Series ultrasound systems. Voluson Expert 22, 20 and 18 combine high resolution image quality with advanced ultrasound technology and an ergonomic design for efficient workflow and a world-class user experience. The Voluson Expert Series integrates artificial intelligence (AI)-powered features and automation tools to help drive imaging performance and efficiencies in women’s healthcare.

Approximately 30,000 to 50,000 women in the United States experience complex, high-risk pregnancy each year.i When these complications are left undetected or untreated, it may harm the mother or the baby. The growing prevalence of these complicationsii underscores the need for innovative solutions that enable early detection and intervention.

The Voluson Expert Series, GE HealthCare’s most advanced women’s health ultrasound systems, offers premium ultrasound imaging for confident diagnoses for high risk, complex pregnancies. The Lyric Architecture is designed to unlock new imaging and processing power to deliver detailed and uniform images and reveal finer details within the anatomy with ease, even in difficult scanning conditions. AI-enabled functionality and automation tools are available to support faster assessments and early detection, diagnosis and intervention.

The SonoLyst suite of AI tools were designed to simplify exams through image recognition and automated annotations and measurements, increasing exam speed and accuracy. With this new release, clinicians can now utilize SonoLystlive during 11 to 14-week anatomical exams helping ensure required views are captured for diagnostic accuracy.  In addition, Voluson Expert Series ultrasound systems feature an expanded color Doppler offering, Graphicflow, which provides a graphical representation of the trajectories of the blood cells in real-time to visualize complex blood flow quickly and clearly, helping users differentiate normal from abnormal hemodynamics.

Voluson Expert Series also includes additional enhancements to select Voluson AI tools:

  • SonoPelvicFloor3.0 can help reduce pelvic floor measurement exam time by 80%.* This feature now expands anatomical views, and simplifies the exam process by automating plane alignment, live C-plane tracking, and measurements.
  • SonoAVCfollicle2.0 uses AI to increase accuracy and precision in follicle detection, resulting in a better success rate of detecting follicles, along with reduced artifacts and requiring less time for postprocessing.

These systems are compatible with a wide selection of unique specialty probes, including a new lightweight 2D/3D probe RAB7-D, and wireless Vscan Air™ dual probes.

“We are proud to introduce these updates to the Voluson Expert ultrasound systems, which represent our ongoing commitment to advancing technology that addresses women's health needs of today, and the future,” said Gerald Seifriedsberger, General Manager, Women’s Health, Advanced Visualization Solutions, GE HealthCare. “By introducing solutions that offer unparalleled clarity and detail, we can empower users with critical insights for informed care decisions and efficient exams, transforming how clinicians approach healthcare. Together, we can create a healthier future for all women.”

GE HealthCare will showcase the Voluson Expert series ultrasound systems at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting™ taking place on January 27-February 1 in Denver. The Voluson Expert Series is available in the United States. For more information on the Voluson Expert Series, visit: https://www.gehealthcare.com/products/ultrasound/voluson.

*Versus manual exam

___________________________________

i Cleveland Clinic. High-Risk Pregnancy. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22190-high-risk-pregnancy. Last reviewed July 12, 2024. Accessed January 17, 2025.

ii Barfield WD, Besera G, Cox S, Warner L, Azeez O, Riggs J, Russell R, Bowron S, Churchill RE. From Data to Action: CDC's Public Health Surveillance for Women, Infants, and Children. 2nd ed. Centers for Disease Control and Prevention; 2020. https://www.cdc.gov/reproductive-health/media/pdfs/data-to-action/Data-To-Action_508.pdf. Accessed January 17, 2025.

 

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  230.59
+0.92 (0.40%)
AAPL  279.10
+2.13 (0.77%)
AMD  213.35
+7.22 (3.50%)
BAC  53.09
+0.61 (1.15%)
GOOG  318.88
-4.76 (-1.47%)
META  636.46
+0.24 (0.04%)
MSFT  486.94
+9.95 (2.09%)
NVDA  181.02
+3.20 (1.80%)
ORCL  205.69
+8.66 (4.40%)
TSLA  420.35
+0.95 (0.23%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.